Apimeds Pharmaceuticals US, Inc. - APUS

Sector: Healthcare · Industry: Pharmaceutical Preparations
Website: No information yet · Social: No information yet

Company profile

Powered by TradingView

Quarter snapshot

Latest / Compare
Q3 2025 · Q2 2025
Value (USD)
Total reported value ($000)
$710K
QoQ value delta ($000)
+$221K (+45.19%)
Implied price effect (QoQ)
+1.11%
Shares
Total shares
399,983
QoQ shares delta
+121,452 (+43.6%)
Total shares held by funds (by quarter)
Shares (left)

Fund holders include prior positions carried forward until a new 13F confirms a change. Reported holders have reported a position in this security for that quarter; this is not the total number of 13F filers.

Market chart (APUS)

Powered by TradingView
Interactive chart by TradingView.

Top holders (Q3 2025)

Top 25 only Full list
Early Q2 2026 data: only 7 institutional holders reported so far. More will appear as funds file with the SEC.
Manager Value ($000) Shares % of 13F
Hemenway Trust Co LLC 445 250,000 0.03%
VANGUARD GROUP INC 105 58,992 0.0%
GEODE CAPITAL MANAGEMENT, LLC 54 30,754 0.0%
RENAISSANCE TECHNOLOGIES LLC 49 27,893 0.0%
XTX Topco Ltd 33 18,735 0.0%
HRT FINANCIAL LP 24 13,572 0.0%
JPMORGAN CHASE & CO 0 8 0.0%
BANK OF AMERICA CORP /DE/ 0 29 0.0%